Omnicell, Inc. (NASDAQ:OMCL) Position Boosted by Trillium Asset Management LLC

Trillium Asset Management LLC grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 12.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,115 shares of the company’s stock after purchasing an additional 16,040 shares during the period. Trillium Asset Management LLC owned approximately 0.31% of Omnicell worth $6,416,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of OMCL. Smartleaf Asset Management LLC lifted its stake in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after buying an additional 273 shares in the last quarter. Van ECK Associates Corp lifted its stake in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares in the last quarter. KBC Group NV lifted its stake in Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after buying an additional 778 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Omnicell by 307.8% during the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock valued at $159,000 after buying an additional 2,699 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Price Performance

Shares of OMCL opened at $34.70 on Thursday. The firm has a market cap of $1.62 billion, a PE ratio of 128.52, a PEG ratio of 7.53 and a beta of 0.85. The firm’s 50 day moving average price is $40.10 and its 200 day moving average price is $43.04. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on OMCL. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Benchmark reissued a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus target price of $52.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.